Report
Pharmaceuticals: Read across from Q3 figures at Merck and Pfizer for European companies
PharmaceuticalsRead across from Q3 figures at Merck and Pfizer for European companies
A still impressive Keytruda, more leader than ever among PD-(L)1s
Merck: a healthy vaccines business but pressure elsewhere
Oncology up 30% at Pfizer in Q3
Eliquis and Xeljanz still strong, biosimilars are progressing
Provider
Bryan Garnier
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Eric Le Berrigaud
Other Reports from Bryan Garnier
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.